

PATENT



Case #PC25420A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Charlotte Moira Norfor Allerton

SERIAL NO.: 10/727,168

FILED: December 2, 2003

TITLE: Morpholine Dopamine Agonists

GROUP ART UNIT: 1626

EXAMINER: Kamal A. Saeed

DATE: June 15, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner for Patents
Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement supplements the Information Disclosure Statement previously submitted. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 161445.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Philip B. Polster II".

Philip B. Polster II
Attorney for Applicants
Registration No. 43,864
Tel: 314-274-9094

Pharmacia Corporation
of Pfizer Inc
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63306



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: PC25420A	APPLICATION NO.: 10/727,168
	INVENTOR: Charlotte Moira Norfor Allerton	
	Filed: 12/2/2003	Group: 1626

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,258,513	11/2/93	Van Keulen	C07D	251/08	
	A2	5,348,956	9/20/94	Van Keulen	A61K	31/535	

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Y	No
	B1	WO92/18489	10/29/1992	PCT	C07D	265/30		
	B2	GB851311A	10/12/60	GB	C07D			
	B3	SU1154907 A1	9/20/96	SU	C07D	295/12		
	B4	RU2095353 C1	10/11/97	RU	C07D	251/12		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	